CA2881321A1 - Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases - Google Patents

Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases Download PDF

Info

Publication number
CA2881321A1
CA2881321A1 CA2881321A CA2881321A CA2881321A1 CA 2881321 A1 CA2881321 A1 CA 2881321A1 CA 2881321 A CA2881321 A CA 2881321A CA 2881321 A CA2881321 A CA 2881321A CA 2881321 A1 CA2881321 A1 CA 2881321A1
Authority
CA
Canada
Prior art keywords
cndot
deficiency
mitochondria
mitochondrial
microglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2881321A
Other languages
English (en)
French (fr)
Inventor
Bo Akerstrom
Magnus Gram
Lena Rosenlof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guard Therapeutics International AB
Original Assignee
A1M Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma AB filed Critical A1M Pharma AB
Publication of CA2881321A1 publication Critical patent/CA2881321A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2881321A 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases Abandoned CA2881321A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (1)

Publication Number Publication Date
CA2881321A1 true CA2881321A1 (en) 2014-03-13

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881321A Abandoned CA2881321A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Country Status (21)

Country Link
US (1) US10226507B2 (enExample)
EP (1) EP2900254B1 (enExample)
JP (2) JP2015533790A (enExample)
KR (1) KR20150047510A (enExample)
CN (1) CN104661673A (enExample)
AU (1) AU2013311714C1 (enExample)
BR (1) BR112015003957A2 (enExample)
CA (1) CA2881321A1 (enExample)
DK (1) DK2900254T3 (enExample)
EA (1) EA028963B1 (enExample)
ES (1) ES2599034T3 (enExample)
HR (1) HRP20161364T1 (enExample)
HU (1) HUE030559T2 (enExample)
IN (1) IN2015DN00515A (enExample)
MX (1) MX357656B (enExample)
NZ (1) NZ629621A (enExample)
PL (1) PL2900254T3 (enExample)
PT (1) PT2900254T (enExample)
SG (1) SG11201500669SA (enExample)
WO (1) WO2014037390A1 (enExample)
ZA (1) ZA201500547B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110452980A (zh) * 2019-09-23 2019-11-15 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン
US20190054142A1 (en) * 2016-02-25 2019-02-21 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
US10981963B2 (en) * 2016-03-18 2021-04-20 Guard Therapeutics International AB Alpha-1-microglobulin derived proteins and their use
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
WO2021062007A1 (en) * 2019-09-25 2021-04-01 Cytegen Corp. Treatment of mitochondrial deficits and age-related diseases using blood products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547124A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
EA022609B1 (ru) * 2007-02-12 2016-02-29 А1М Фарма Аб Применение свободного фетального гемоглобина в качестве маркера преэклампсии
ES2560097T3 (es) * 2008-02-04 2016-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Procedimientos y composiciones de tratamiento de trastornos mitocondriales
CA2730531A1 (en) * 2008-07-18 2010-01-21 A1M Pharma Ab Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110452980A (zh) * 2019-09-23 2019-11-15 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用

Also Published As

Publication number Publication date
EA028963B1 (ru) 2018-01-31
MX357656B (es) 2018-07-18
KR20150047510A (ko) 2015-05-04
AU2013311714A1 (en) 2015-03-12
PL2900254T3 (pl) 2017-02-28
JP2015533790A (ja) 2015-11-26
US10226507B2 (en) 2019-03-12
PT2900254T (pt) 2016-10-18
MX2015002604A (es) 2015-06-10
AU2013311714C1 (en) 2018-01-25
CN104661673A (zh) 2015-05-27
HRP20161364T1 (hr) 2016-12-16
NZ629621A (en) 2015-09-25
WO2014037390A1 (en) 2014-03-13
US20150258171A1 (en) 2015-09-17
JP2018203756A (ja) 2018-12-27
IN2015DN00515A (enExample) 2015-06-26
EP2900254B1 (en) 2016-08-03
DK2900254T3 (en) 2016-08-29
HK1210585A1 (en) 2016-04-29
EP2900254A1 (en) 2015-08-05
AU2013311714B2 (en) 2017-10-12
ZA201500547B (en) 2017-09-27
ES2599034T3 (es) 2017-01-31
BR112015003957A2 (pt) 2017-08-08
SG11201500669SA (en) 2015-02-27
HUE030559T2 (en) 2017-05-29
EA201590503A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
EP2900254B1 (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Reddy et al. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases
Britti et al. Frataxin‐deficient neurons and mice models of Friedreich ataxia are improved by TAT‐MTS cs‐FXN treatment
Lim et al. Molecular characterization of the cystine/glutamate exchanger and the excitatory amino acid transporters in the rat lens
CN104023736A (zh) Jnk信号转导途径的细胞-可渗透肽抑制剂用于治疗干眼综合征的用途
ES2992180T3 (es) Mutante de NGF para su uso en el tratamiento o prevención de trastornos oftálmicos
CN100537602C (zh) Ec sod和细胞转导性ec sod及它们的用途
Formichi et al. Analysis of opa1 isoforms expression and apoptosis regulation in autosomal dominant optic atrophy (ADOA) patients with mutations in the opa1 gene
Argenti The role of mitochondrial dysfunction in Huntington's disease: pathogenesis and its relation with striatal Rhes protein
HK1210585B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
Petese et al. Are Lysosomes Potential Therapeutic Targets for Parkinson’s Disease?
Vijayasarathy et al. Organization and molecular interactions of retinoschisin in photoreceptors
RU2812055C1 (ru) Агент для использования при лечении или профилактике офтальмологических расстройств
US20190099468A1 (en) Method to protect and seal the ocular surface
Koskelainen Amyloid angiopathy in hereditary gelsolin amyloidosis
KR101481741B1 (ko) Ⅰｇｆ­１을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법
Raschke Mammalian m-AAA Proteases as key regulators of mitochondrial function: analysis of dominant negative mutant variants
Deheshi Mitochondrial form and function: an investigation of the mechanism and significance of mitochondrial remodelling in rat cortical astrocytes
Zhonga et al. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-PI3K-Akt pathway through its SHBG-like region
Yaung Protective mechanisms against oxidative stress in retinal pathogenesis
CA3001625A1 (en) Compositions and methods for treatment of homocystinuria

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180822

FZDE Discontinued

Effective date: 20220406